Fisher & Paykel Healthcare stock upgraded by CLSA on product innovation

CLSA has upgraded Fisher & Paykel Healthcare (FPH) from Hold to Outperform, increasing its price target to NZD37.80 from NZD34.50. The upgrade is driven by FPH's consistent product innovation, successful expansion of its OptiFlow system beyond intensive care units, and strong launches in its obstructive sleep apnea portfolio. CLSA views FPH's quality as justifying a premium valuation, considering its current valuation attractive despite tariff headwinds, with potential for sales growth from rising COVID-19 cases in H2 FY26.

Analysis

CLSA has upgraded Fisher & Paykel Healthcare (FPH) to Outperform from Hold, raising its price target to NZD37.80 from NZD34.50. This upgrade is fundamentally driven by the company's successful product innovation and market expansion strategy. Specifically, CLSA highlights the growing adoption of FPH's OptiFlow system outside of traditional intensive care units, indicating a broadening addressable market. This is complemented by strong traction from new high-quality product launches within its obstructive sleep apnea (OSA) portfolio. From a valuation standpoint, CLSA views FPH's current market price as 'attractive' and asserts that the company's quality justifies a premium valuation, even in the face of persistent tariff headwinds. While the firm remains cautious, it also notes that a potential resurgence in COVID-19 cases could provide a sales tailwind in the second half of fiscal year 2026, adding a speculative but positive catalyst to the outlook.

Key Decisions for Investors

• Investors with a bullish outlook on the healthcare sector may consider the 'Outperform' rating and attractive valuation assessment as a signal to initiate or add to positions in FPH.
• It is crucial to monitor the sales momentum of the OptiFlow system in non-ICU settings and the performance of new OSA products, as these are the key growth drivers underpinning CLSA's thesis.
• While the outlook is positive, investors should factor in the potential margin impact from 'tariff headwinds' and treat the potential H2 FY26 sales boost from COVID-19 as an uncertain but possible upside.